Loading...
Loading...
Canaccord Genuity provided some remarks on three companies after attending the "American Society for Microbiology" forum. According to the report published Monday, the Canaccord Genuity analysts are positive on
GenMark Diagnostics, IncGNMK and
T2 Biosystems Inc TTOO, and they expect
Accelerate Diagnostics IncAXDX to remain a key player to follow in 2016–2017.
The analysts noted it is possible to see "additional consolidation as upstart growth companies enter new verticals, or eat into the shares of the incumbents," despite a strong competition in infectious disease. Strong traffic was noticed in booths of all three companies during the exhibition.
At Time Of Writing...
- Accelerate was down 4.41 percent at $14.30 on the day.
- T2 was down 2.47 percent at $8.29.
- GenMark was down 3.95 percent at $8.02.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorBiotechLong IdeasNewsHealth CareEventsAnalyst RatingsMoversTrading IdeasGeneralAmerican Society For MicrobiologyCanaccord GenuityMicrobiology
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in